Semaglutide for Metabolic Dysfunction–Associated Steatohepatitis
New England Journal of Medicine · 05.06.2025 · 392 (21) · 2160-2161
DOI: 10.1056/nejme2504717 ↗Kurz gefasst
Editorial in der Zeitschrift New England Journal of Medicine, erschienen am 05.06.2025. Verfasst von Tracey G Simon. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease that affects more than 30% of adults worldwide. 1 Up to one third of patients with MASLD have progressive steatohepatitis (MASH) and fibrosis, which can lead to cirrhosis and death. 2 MASH is also associated with an excess risk of cardiovascular disease, a finding that underscores the importance of simultaneously addressing cardiometabolic risk factors in the treatment of this disease. 2 Currently, the only medication conditionally approved for the treatment of MASH with fibrosis is resmetirom — a liver-directed thyroid hormone receptor beta-selective agonist. Thus, additional therapies are still . . .
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston.
- Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston.
- Harvard Medical School, Boston.
- Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston.
ORCID-Profile: Tracey G Simon
Zitieren
APA
Simon, T. G. (2025). Semaglutide for Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine, 392(21), 2160-2161. https://doi.org/10.1056/nejme2504717
Vancouver
Simon TG. Semaglutide for Metabolic Dysfunction–Associated Steatohepatitis. New England Journal of Medicine. 2025;392(21):2160-2161. doi:10.1056/nejme2504717
BibTeX
@article{Simon2025,
author = {Simon, Tracey G},
title = {Semaglutide for Metabolic Dysfunction–Associated Steatohepatitis},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {21},
pages = {2160--2161},
doi = {10.1056/nejme2504717}
}
EUVIMED